Related Experiment Video
Updated: Jan 16, 2026
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary Hypertension
Background:
Cardiometabolic disease is a leading cause of pulmonary hypertension (PH), a progressive condition that increases the risk of death and heart failure hospitalization. Preventive therapies are lacking, and Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a promising intervention due to their broad cardiometabolic benefits. Therefore, this study was designed to determine whether GLP-1 RA exposure is associated with reduced risk for developing PH.
Methods:
We conducted a retrospective cohort study using data from the Veterans Health Administration. Patients with diabetes and an echocardiogram without PH who initiated a GLP-1 RA or Dipeptidyl Peptidase 4 inhibitor (DPP-4i) between January 1, 2007 and December 31, 2021 were included in the study. We used the active comparator, new user design to emulate a pragmatic clinical trial and employed inverse probability weighting (IPW) to adjust for confounding. GLP-1 RA new users were compared to DPP-4i new users. Patients were followed from first prescription date (baseline) until PH diagnosis, death, or medication cessation (latest date April 30, 2022). The primary outcome was development of PH, defined by an echocardiographic estimated right ventricular systolic pressure of 35 mmHg or greater.
Results:
We identified 4,109 GLP-1 RA users and 7,384 DPP-4i users without PH at baseline. In comparison to DPP4i users, GLP-1 RA users were younger (median [Q1-Q3], 69 [63-73] vs 70 [65-74]) and similar in sex distribution (94.6% vs 95.6% male). Unadjusted incidence rates of PH for GLP-1 RA compared to DPP-4i were 54.8 vs 69.7 cases per 1000 person-years. IPW achieved covariate balance between groups (all standardized mean differences <0.10). In Cox regression models on the IPW cohort, GLP-1 RA exposure compared to DPP-4i exposure was associated with a 28% reduced risk of developing PH (HR, 0.72; 95%CI 0.61-0.84). Reduced risk of PH associated with GLP-1 RA use was consistent across sensitivity and subgroup analyses, including when stratified by obesity and diabetes severity.
Conclusions:
GLP-1 RA use was associated with a reduced risk of developing PH. This finding supports the need for clinical trials and mechanistic studies to evaluate the potential role of GLP-1 RA therapy in the prevention of PH.
Insights
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may reduce the risk of developing pulmonary hypertension (PH) in patients with diabetes. This study found GLP-1 RA use was associated with a 28% lower risk of PH compared to DPP-4 inhibitors.
Area of Science:
- Cardiology
- Endocrinology
- Pulmonology
Background:
- Cardiometabolic disease is a primary driver of pulmonary hypertension (PH), a condition linked to increased mortality and heart failure hospitalizations.
- Preventive strategies for PH are limited, highlighting the need for novel therapeutic approaches.
- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiometabolic benefits, positioning them as a potential intervention for PH prevention.
Purpose of the Study:
- To investigate the association between Glucagon-like peptide 1 receptor agonist (GLP-1 RA) exposure and the risk of developing pulmonary hypertension (PH).
- To evaluate the potential of GLP-1 RAs as a preventive therapy for PH in patients with diabetes.
Main Methods:
- A retrospective cohort study utilizing Veterans Health Administration data.
- Inclusion criteria: patients with diabetes and an echocardiogram without PH, initiating either a GLP-1 RA or a Dipeptidyl Peptidase 4 inhibitor (DPP-4i).
- Inverse probability weighting (IPW) was used to adjust for confounding factors, comparing new users of GLP-1 RAs to new users of DPP-4is.
Main Results:
- The study included 4,109 GLP-1 RA users and 7,384 DPP-4i users; GLP-1 RA users were slightly younger.
- Inverse probability weighting achieved covariate balance between the two groups.
- GLP-1 RA exposure was associated with a 28% reduced risk of developing PH compared to DPP-4i exposure (HR, 0.72; 95% CI 0.61-0.84).
Conclusions:
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is linked to a decreased risk of pulmonary hypertension (PH) development.
- These findings warrant further investigation through clinical trials and mechanistic studies.
- GLP-1 RAs may hold potential as a preventive therapy for PH, particularly in at-risk populations.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:06Oral Hypoglycemic Agents: Glinides
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Dipeptidyl Peptidase 4 Inhibitors